{
  "main_header": {
    "sid": 178818,
    "name": "Ajanta Pharma",
    "stock_name": "Ajanta Pharma",
    "full_name": "Ajanta Pharma Ltd.",
    "name_url": "stocks-analysis/ajanta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,638.15",
    "chg": -0.9,
    "chgp": "-0.03%",
    "dir": -1,
    "prev_price": "2,639.05",
    "mcapval": "32,960.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532331,
    "symbol": "AJANTPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE031B01049",
    "curr_date": "Dec 15",
    "curr_time": "",
    "bse_nse_vol": "16.43 k",
    "exc_status": "Active",
    "traded_date": "Dec 15, 2025",
    "traded_date_str": "2025 12 15",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajanta-pharma-178818-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Ajanta Pharma's Market Assessment Reflects Mixed Signals Amidst Flat Financials and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-downgraded-to-sell-amid-technical-weakness-and-valuation-concerns-3759469",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AjantaPharma_mojoScore_3759469.png",
        "date": "2025-12-16 08:13:40",
        "description": "Ajanta Pharma's recent market evaluation reveals a nuanced picture shaped by flat quarterly financials, valuation considerations, and evolving technical indicators. While the company maintains strong management efficiency and institutional interest, shifts in technical trends and valuation metrics have influenced the overall market assessment."
      },
      {
        "title": "Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-technical-momentum-shifts-amid-mixed-market-signals-3759284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AjantaPharma_technicaldot_3759284.png",
        "date": "2025-12-16 08:01:45",
        "description": "Ajanta Pharma's recent price momentum reveals a nuanced shift in technical indicators, reflecting a complex interplay of mildly bearish and bullish signals across multiple timeframes. The stock's current trading dynamics, combined with its relative performance against the Sensex, offer investors a detailed perspective on its evolving market stance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ajanta Pharma's Market Assessment Reflects Mixed Signals Amidst Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-upgraded-to-hold-by-marketsmojo-amid-mixed-financial-and-technical-signals-3754743",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AjantaPharma_mojoScore_3754743.png",
        "date": "2025-12-10 08:10:38",
        "description": "Ajanta Pharma's recent market evaluation reveals a nuanced picture shaped by technical indicators, valuation considerations, financial trends, and quality metrics. Despite flat quarterly financial performance, the company's standing in the Pharmaceuticals & Biotechnology sector continues to attract attention due to its strong management efficiency and institutional backing."
      },
      {
        "title": "Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-technical-momentum-shifts-amid-mixed-market-signals-3754603",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AjantaPharma_technicaldot_3754603.png",
        "date": "2025-12-10 08:01:09",
        "description": "Ajanta Pharma's recent trading activity reveals a nuanced shift in technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The stock's price movement and key technical indicators suggest a transition from a mildly bearish trend to a more sideways pattern, prompting investors to reassess the pharmaceutical company's near-term outlook."
      },
      {
        "title": "Why is Ajanta Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ajanta-pharma-fallingrising-3742384",
        "imagepath": "",
        "date": "2025-12-03 00:36:36",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Outperformance</strong></p>\n<p>Ajanta Pharma's stock has demonstrated resilience in the short term, outperforming its sector by 1.08% on the day. The stock has been on a three-day consecutive gain streak, delivering a cumulative return of 2.24% over this period. This upward trajectory is supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained buying interest and positive technical momentum.</p>\n<p>Investor participation has also increased, with delivery volumes on 01 Dec rising by over 20% compared to the five-day average, indicating heightened confidence among market participants. The stock's liquidity remains adequate, allowing for trade sizes of approximately ₹0...."
      },
      {
        "title": "Ajanta Pharma’s Evaluation Revised Amidst Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-and-trend-concerns-3730718",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AjantaPharma_mojoScore_3730718.png",
        "date": "2025-11-26 09:46:59",
        "description": "Ajanta Pharma has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and a complex interplay of valuation and operational metrics within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Ajanta Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ajanta-pharma-technically-bullish-or-bearish-3727461",
        "imagepath": "",
        "date": "2025-11-25 08:29:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Technical Trend Shift</strong></p>\n<p>As of 24 Nov 2025, Ajanta Pharma’s technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle change suggests that while the stock is not yet in a confirmed uptrend, the intensity of selling pressure has eased somewhat. Investors should note that a mildly bearish trend often indicates consolidation or a potential base-building phase before a decisive move.</p>\n<p><strong>Momentum Indicators: Mixed Signals</strong></p>\n<p>Examining momentum oscillators reveals a complex scenario. The Moving Average Convergence Divergence (MACD) indicator shows a mildly bullish signal on the weekly chart, hinting at some short-term upward momentum. However, the monthly MACD remains mildly bearish, reflecting longer-term caution..."
      },
      {
        "title": "Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-technical-momentum-shifts-amid-mixed-indicator-signals-3727310",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AjantaPharma_technicaldot_3727310.png",
        "date": "2025-11-25 08:01:13",
        "description": "Ajanta Pharma's recent price momentum reflects a nuanced shift in technical indicators, signalling a transition from a predominantly bearish stance to a more balanced outlook. The stock's performance, juxtaposed with key technical metrics such as MACD, RSI, and moving averages, reveals a complex market assessment amid broader sector dynamics."
      },
      {
        "title": "Ajanta Pharma Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-faces-bearish-momentum-amid-mixed-technical-signals-3723615",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AjantaPharma_technicaldot_3723615.png",
        "date": "2025-11-24 08:00:37",
        "description": "Ajanta Pharma's recent price action reflects a notable shift in technical momentum, with a blend of bearish and bullish signals emerging across key indicators. The stock's current trading dynamics and comparative performance against benchmarks warrant close examination for investors navigating the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 588,
    "sid": "178818",
    "stock_news_url": "https://www.marketsmojo.com/news/ajanta-pharma-178818"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "10-Dec-2025",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on December 10 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "28-Nov-2025",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 26 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "13-Nov-2025",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 13 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has declared <strong>1400%</strong> dividend, ex-date: 10 Nov 25",
          "dt": "2025-11-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15",
          "dt": "2015-03-20",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22",
          "dt": "2022-06-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ajanta Pharma's Market Assessment Reflects Mixed Signals Amidst Flat Financials and Technical Shifts

2025-12-16 08:13:40

Ajanta Pharma's recent market evaluation reveals a nuanced picture shaped by flat quarterly financials, valuation considerations, and evolving technical indicators. While the company maintains strong management efficiency and institutional interest, shifts in technical trends and valuation metrics have influenced the overall market assessment.

Read More

Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-16 08:01:45

Ajanta Pharma's recent price momentum reveals a nuanced shift in technical indicators, reflecting a complex interplay of mildly bearish and bullish signals across multiple timeframes. The stock's current trading dynamics, combined with its relative performance against the Sensex, offer investors a detailed perspective on its evolving market stance within the Pharmaceuticals & Biotechnology sector.

Read More

Ajanta Pharma's Market Assessment Reflects Mixed Signals Amidst Flat Financials

2025-12-10 08:10:38

Ajanta Pharma's recent market evaluation reveals a nuanced picture shaped by technical indicators, valuation considerations, financial trends, and quality metrics. Despite flat quarterly financial performance, the company's standing in the Pharmaceuticals & Biotechnology sector continues to attract attention due to its strong management efficiency and institutional backing.

Read More

Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-10 08:01:09

Ajanta Pharma's recent trading activity reveals a nuanced shift in technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The stock's price movement and key technical indicators suggest a transition from a mildly bearish trend to a more sideways pattern, prompting investors to reassess the pharmaceutical company's near-term outlook.

Read More

Why is Ajanta Pharma falling/rising?

2025-12-03 00:36:36

Recent Price Movement and Market Outperformance

Ajanta Pharma's stock has demonstrated resilience in the short term, outperforming its sector by 1.08% on the day. The stock has been on a three-day consecutive gain streak, delivering a cumulative return of 2.24% over this period. This upward trajectory is supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained buying interest and positive technical momentum.

Investor participation has also increased, with delivery volumes on 01 Dec rising by over 20% compared to the five-day average, indicating heightened confidence among market participants. The stock's liquidity remains adequate, allowing for trade sizes of approximately ₹0....

Read More

Ajanta Pharma’s Evaluation Revised Amidst Mixed Financial and Market Signals

2025-11-26 09:46:59

Ajanta Pharma has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and a complex interplay of valuation and operational metrics within the Pharmaceuticals & Biotechnology sector.

Read More

Is Ajanta Pharma technically bullish or bearish?

2025-11-25 08:29:32

Recent Technical Trend Shift

As of 24 Nov 2025, Ajanta Pharma’s technical trend has transitioned from a clear bearish stance to a mildly bearish one. This subtle change suggests that while the stock is not yet in a confirmed uptrend, the intensity of selling pressure has eased somewhat. Investors should note that a mildly bearish trend often indicates consolidation or a potential base-building phase before a decisive move.

Momentum Indicators: Mixed Signals

Examining momentum oscillators reveals a complex scenario. The Moving Average Convergence Divergence (MACD) indicator shows a mildly bullish signal on the weekly chart, hinting at some short-term upward momentum. However, the monthly MACD remains mildly bearish, reflecting longer-term caution...

Read More

Ajanta Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:01:13

Ajanta Pharma's recent price momentum reflects a nuanced shift in technical indicators, signalling a transition from a predominantly bearish stance to a more balanced outlook. The stock's performance, juxtaposed with key technical metrics such as MACD, RSI, and moving averages, reveals a complex market assessment amid broader sector dynamics.

Read More

Ajanta Pharma Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-24 08:00:37

Ajanta Pharma's recent price action reflects a notable shift in technical momentum, with a blend of bearish and bullish signals emerging across key indicators. The stock's current trading dynamics and comparative performance against benchmarks warrant close examination for investors navigating the Pharmaceuticals & Biotechnology sector.

Read More

View All News